Where does pharma’s reshoring push stand today, and what comes next? Reshoring Institute Executive Director Rosemary Coates explains the industry’s unique advantage and the hurdles still in the way.

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. While methodological changes may have affected the result, the dip highlights a period when drugmakers have trimmed their pipelines and cut the number of new projects starting development.

The president has rolled out a 100% tariff rate on patented pharmaceutical products and ingredients following a “Section 232” investigation, according to a White House fact sheet.

The U.K.’s end of the deal requires it to spend more on drugs through its National Health Service, which it is implementing through a higher cost-effectiveness threshold for its National Institute for Health and Care Excellence (NICE).

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Keenan discussed how she landed on the tech side of pharma marketing, how lived experiences can influence campaigns, and what spinning tunes and serving up ads have in common.

BioNTech is turning out the lights at the Singapore plant it purchased from Novartis at the height of the COVID-19 outbreak, reflecting a sharp reversal in the mRNA specialist’s trajectory since the pandemic’s end.